These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31462520)

  • 21. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3,4-methylenedioxymethamphetamine (MDMA): a review.
    O'Leary G; Nargiso J; Weiss RD
    Curr Psychiatry Rep; 2001 Dec; 3(6):477-83. PubMed ID: 11707161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.
    Monks TJ; Jones DC; Bai F; Lau SS
    Ther Drug Monit; 2004 Apr; 26(2):132-6. PubMed ID: 15228153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings.
    Bonsignore A; Barranco R; Morando A; Fraternali Orcioni G; Ventura F
    Cardiovasc Toxicol; 2019 Dec; 19(6):493-499. PubMed ID: 31073690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment.
    Logan BK; Couper FJ
    J Forensic Sci; 2001 Nov; 46(6):1426-33. PubMed ID: 11714155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How MDMA's pharmacology and pharmacokinetics drive desired effects and harms.
    Michael White C
    J Clin Pharmacol; 2014 Mar; 54(3):245-52. PubMed ID: 24431106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine.
    Traub SJ; Hoffman RS; Nelson LS
    J Urban Health; 2002 Dec; 79(4):549-55. PubMed ID: 12468674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series.
    Armenian P; Mamantov TM; Tsutaoka BT; Gerona RR; Silman EF; Wu AH; Olson KR
    J Intensive Care Med; 2013; 28(4):252-8. PubMed ID: 22640978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3,4-methylenedioxymethamphetamine (MDMA): an important cause of acute hepatitis.
    Brncić N; Kraus I; Visković I; Mijandrusić-Sincić B; Vlahović-Palcevski V
    Med Sci Monit; 2006 Nov; 12(11):CS107-9. PubMed ID: 17072276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ecstasy (MDMA) and oral health.
    Brand HS; Dun SN; Nieuw Amerongen AV
    Br Dent J; 2008 Jan; 204(2):77-81. PubMed ID: 18268544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance.
    Lamers CT; Ramaekers JG; Muntjewerff ND; Sikkema KL; Samyn N; Read NL; Brookhuis KA; Riedel WJ
    J Psychopharmacol; 2003 Dec; 17(4):379-87. PubMed ID: 14870949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review.
    Garg A; Kapoor S; Goel M; Chopra S; Chopra M; Kapoor A; McCann UD; Behera C
    Curr Drug Abuse Rev; 2015; 8(1):15-25. PubMed ID: 25731754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion.
    Farah R; Farah R
    Pediatr Emerg Care; 2008 Sep; 24(9):615-7. PubMed ID: 18797371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.
    Antolino-Lobo I; Meulenbelt J; van den Berg M; van Duursen MB
    Vet Q; 2011 Dec; 31(4):193-205. PubMed ID: 22151050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute liver failure following the use of ecstasy (MDMA)].
    Lange-Brock N; Berg T; Müller AR; Fliege H; Neuhaus P; Wiedenmann B; Klapp BF; Mönnikes H
    Z Gastroenterol; 2002 Aug; 40(8):581-6. PubMed ID: 12297982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered states: the clinical effects of Ecstasy.
    Cole JC; Sumnall HR
    Pharmacol Ther; 2003 Apr; 98(1):35-58. PubMed ID: 12667887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology.
    Rochester JA; Kirchner JT
    J Am Board Fam Pract; 1999; 12(2):137-42. PubMed ID: 10220237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.